Pharma join together to achieve new standards in digital and patient innovation for clinical transformation

Reuters Events 17 - 19 May 2022, Virtual.
On May 17th , 500+ of pharma's clinical innovation will come together for the home of clinical collaboration, Reuters Events: Pharma Clinical 2022, to set new standards in digital and patient innovation for clinical transformation.

The catalyst for this has been the accelerated technological adoption in clinical trials, but a general feeling still that enough isn't being done for patients, failing to develop co-created, data-driven, standardised and accountable trial design.

Senior leaders from Sanofi, Pfizer, Bayer, FDA, AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Roche, Novartis and more are collaborating on May 17 th , with one mission in mind: it's time to develop a better system. "We must establish new industry-wide benchmarks, leverage digital technology, and ensure permanent cultural change toward patient- centric trials. If we don't act immediately, we risk losing patient trust." Said Usmaan Khan, Global Project Director and leader for Reuters Events: Pharma Clinical 2022.

The community is growing every day so don't miss out on the opportunity to be part of this movement- this event is free for pharma and biotech executives, patient advocates and patient associations! Secure your pass today here.

About Reuters Events: Pharma Clinical 2022, May 17-19th

Reuters Events: Pharma Clinical is proud to host a one-of-a-kind lineup, with more than 40 world-class and professional speakers. Among the speakers are:
  • Jijo James, CMO, Medical Devises, Johnson & Johnson
  • Lionel Bascles, SVP, Global Head of Clinical Sciences & Operations, Sanofi
  • Craig Lipset, Advisor and founder, Clinical Innovations Partners
  • Loredana Regep, VP Medical and Regulatory Affairs, Roche
  • Najat Khan, Chief Data Science Officer, Global Head, Janssen R&D Strategy and Operations, Johnson & Johnson
  • Dietmar Berger, CMO, Global Head of Development, Sanofi
  • Tracy Vanderslice, VP & Head, Pharma Global Clinical Operations, GSK
  • Venkat Sethuraman, SVP Global Biometrics and Data Science, Bristol-Myers Squibb

Click here to discover the full speaker line-up now!

Why should you attend?

On last year's event, Mo Ali, VP Digital Analytics and Performance said: "Clinical 2021 allows for open discussions around how we can do this, by sharing experiences and learnings, we expand on the art of the possible from what once several years ago may have been viewed as impossible"

Clinical 2022 builds on this with our insight-driven agenda co-created with industry leaders to guarantee you acquire practical knowledge that will help you succeed. With 40+ speakers, you'll access critical sessions related to:

  • Benchmark industry-wide clinical innovation: Align standards across stakeholders, establish benchmarks, maintain accountability, and set industry-wide goals to improve patient experience and trial performance
  • Co-creation or no creation: Create shared missions, education programmes, and centre digital advances around patients to create trial designs that work in the real world
  • Optimise your digital and data strategies for novel endpoints: Develop trial flexibility, design efficiency, and unique RWE endpoints through standardised and tested innovations
  • Data collaboration: Ensure smooth interoperable data transmissions across the company's digital innovation and health networks for streamlined trials
  • Evolve decentralised trials: Allow decentralised trials to thrive by providing ongoing trial breakthroughs that are backed by regulators and prioritise the patient.

Interested in sponsoring or speaking at Clinical 2022? Fill out the form here.

For further information and to register, please visit Pharma Clinical 2022

About Reuters Events

Our mission is to make pharma more open and valued.

More open so that the strongest ideas and insights are brought to the fore in a transparent, trustworthy manner. More valued by having an authentic approach to building products and services that matter to patients.

To do this, Reuters Events provides a hub for senior-level pharma executives, patient groups and other health stakeholders to exchange ideas and observe shifting trends and practices. We provide commentary, events, reports, and other expert-driven content. One of our biggest strengths is to be able to gather advice, examples and understanding on the best industry work, articulate this across multiple channels, and create a mass movement to help us all improve. This is how we will serve patients better.

We actively respond to the aims and interests of our audience, so please get in touch if you think we can do more.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...